Business Today – 24 May 2026

Summary

Sun Pharma paid 8.5 billion dollars for Organon, giving Dilip Shanghvi control of a sales network spanning 150 countries — Business Today's May 24, 2026 issue (Vol 35 No 11) puts the deal at the centre of a cover story titled "Global Ambitions." The lead essay examines whether Indian pharma can sustain cross-border acquisitions at this scale. GIFT City's long-delayed moment of truth arrives as the first international banks set up shop, and the IPL's evolution into a serious institutional asset class gets a dedicated feature.

The cover story tracks Sun Pharma's integration roadmap: Organon adds women's health and biosimilar portfolios that Sun could not have built organically in less than a decade. The finance section reports on GIFT City's progress, with 6 global banks now holding operational licences. An IPL feature examines how private equity funds are valuing franchise stakes at 30-40 percent above 2024 levels.

Regular sections include The Point, BT Interview, Finance, and Industry reporting. The issue also covers India's Kalpakkam fast-breeder reactor milestone.

—————

Content Guide

▸ Cover Story / Pharma

p.18 · Global Ambitions
Sun Pharma's 8.5-billion-dollar acquisition of Organon creates a top-5 global generics player with operations in 150 countries. The article breaks down the financing structure: 5.5 billion dollars in debt, 3 billion in cash reserves, and a planned asset sale of 500 million dollars to trim leverage. Organon's women's health portfolio contributed 1.6 billion dollars in 2025 revenue. Pharma M&A analysts can use the leverage ratio and divestment timeline to model Sun's debt-repayment schedule.

▸ Interview / Real Estate

p.14 · To Benefit from Consolidation in Real Estate
The BT Interview features a leading real estate executive discussing how listed developers are gaining market share from unorganised players in a post-RERA environment. The piece notes that the top 10 listed developers now control 18 percent of the residential market, up from 9 percent in 2020. Real estate investors can use this concentration data to identify acquisition targets.

▸ Finance / Banking

p.32 · GIFT's Moment of Truth
GIFT City now hosts 6 international banks with full operational licences, and the first dollar-denominated bond listing is scheduled for June 2026. The article reports that total assets under management at GIFT-based funds have crossed 45 billion dollars. Treasury teams evaluating offshore banking units should study the tax-neutral structure detailed in this piece.

▸ Markets / Economy

p.10 · Domestic Dominance
The Point column reports that domestic institutional investors pumped 1.8 lakh crore into Indian equities in 2025, offsetting 1.5 lakh crore of foreign outflows. Mutual fund SIPs now account for 14,500 crore per month. The structural shift from FII-driven to DII-driven markets has reduced Nifty's correlation with US interest rates. Asset allocators should revisit their India-beta assumptions.

▸ Sports / Business

p.0 · IPL: Serious Investment Asset
IPL franchise valuations have surged 40 percent since 2024, with the latest media rights deal worth 52,000 crore over 5 years. Private equity funds hold stakes in 5 of the 10 franchises, and the article profiles how PE firms are professionalising team operations. Sports business analysts can use the valuation multiples as a benchmark for emerging-market franchise assets.

▸ Technology / Nuclear Energy

p.0 · Kalpakkam Milestone
India's prototype fast-breeder reactor at Kalpakkam achieved criticality, marking a 40-year project's most significant milestone. The reactor uses thorium as a secondary fuel, aligning with India's long-term energy independence strategy. Energy policy researchers should note the timeline for commercial-scale thorium reactors now projected for 2035.

—————

Editor's Take

The Sun Pharma-Organon cover story is BT at its strongest — a cross-border M&A narrative supported by financing detail, portfolio analysis, and integration timelines. GIFT City's progress report is timely and fills a gap left by daily financial newspapers that rarely revisit a story after the launch event. The IPL valuation feature is a smart addition for the asset-management readership. The weakest element is the absence of a tech or digital feature, which feels like a gap given that two of BT's recent issues had strong tech sections. The Point column continues to deliver compact market intelligence.

Strengths
• Sun Pharma M&A analysis with hard financing numbers
• GIFT City operational update fills a news-stand gap
• IPL valuation multiples provide a useful PE benchmark

Weaknesses
• No dedicated technology or digital section
• Cover story could have included a competition-risk analysis

Verdict: Recommended — The Sun Pharma deal breakdown makes this a must-read for M&A and pharma professionals; GIFT City and IPL features add strong secondary value.